Last reviewed · How we verify
Antibe Therapeutics Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
3 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Pain · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- American University of Beirut Medical Center · 1 shared drug class
- Amneal Pharmaceuticals, LLC · 1 shared drug class
- Apsen Farmaceutica S.A. · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Behar, Caren, M.D. · 1 shared drug class
- Chinese University of Hong Kong · 1 shared drug class
- Generic (originally Syntex) · 1 shared drug class
- Allergan · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Antibe Therapeutics Inc.:
- Antibe Therapeutics Inc. pipeline updates — RSS
- Antibe Therapeutics Inc. pipeline updates — Atom
- Antibe Therapeutics Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Antibe Therapeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/antibe-therapeutics-inc. Accessed 2026-05-17.